Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÆÄÁ¦Æ®º´°ú µ¿¹ÝµÈ À¯¹æ¾Ï¿¡¼­ Anaphase Promoting Complex (APC)¿Í APCÁ¶Àý ´Ü¹éÀÇ ¹ßÇö Expression of Anaphase Promoting Complex (APC) and APC Regulatory Proteins in Invasive Ductal Carcinoma Associated with Paget¢¥s Disease

´ëÇѺ´¸®ÇÐȸÁö 2004³â 38±Ç 5È£ p.319 ~ 323
¹Ú±¤ÇÏ, ¾ç¿ìÀÍ, °­¿±, ÀÌ»ó¿±, À̱¤±æ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú±¤ÇÏ ( Park Kwang-Hwa ) 
¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

¾ç¿ìÀÍ ( Yang Woo-Ick ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
°­¿± ( Kang Yup ) 
¾ÆÁÖ´ëÇб³ ÀÇ°úÇבּ¸¼Ò
À̻󿱠( Yi Sang-Yeop ) 
°üµ¿´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
À̱¤±æ ( Lee Kwang-Gil ) 
¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Background: Oncogene expression in Paget¢¥s disease of the breast is not well known. To characterize invasive ductal carcinoma associated with Paget¢¥s disease, we studied expression of anaphase promoting complex (APC) with its regulatory proteins.

Methods: Immunohistochemical stainings were done with 10 cases of invasive ductal carcinoma associated with Paget¢¥s disease for APC, pituitary tumor transforming gene (PTTG), cyclin B1, p53, cyclin D1, and c-erbB-2. The expressions of these markers in Paget¢¥s disease were compared with those in the associated with carcinoma.

results: APC, PTTG, cyclin B1, and c-erbB-2 were positive in all of the cases with both Paget¢¥s disease and underlying carcinoma. p53 was expressed in Paget¢¥s disease of 6 cases (60%) and in carcinoma of 7 cases (70%). Cyclin D1 was positive in Paget¢¥s disease of 8 cases (80%) and in carcinoma of 9 cases (90%).

Conclusions: Breast carcinomas with Paget¢¥s disease seem to be distinguished by the high expression of APC, cyclin B1, PTTG, c-erbB2, and cyclin D1 in contrast to breast cancers without Paget¢¥s disease. Furthermore, the similar expression patterns of APC and APC regulatory proteins in both Paget¢¥s disease and underlying breast cancer support the epidermotropic theory as its pathogenetic mechanism.

Å°¿öµå

Paget¢¥s disease;Breast cancer;Anaphase Promoting Complex;Cyclin B1;PTTG

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS